Nammi Therapeutics develops targeted immunotherapies using lipid-based nanoparticles to deliver immune-modulating prodrugs directly to tumor sites, minimizing systemic side effects associated with traditional cancer treatments. Their technology addresses the challenge of severe toxicities and inefficiencies in current immunotherapy approaches by activating immune responses specifically within the tumor microenvironment.
Funding
$66.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer immunotherapies often cause severe systemic toxicities due to widespread immune activation throughout the body. Current approaches struggle to selectively target the tumor microenvironment, leading to off-target effects and limiting the efficacy of treatment. Redundant regulatory pathways controlling immune functions require intervention in multiple processes to stimulate and maintain an effective anti-tumor response.
Solution
Nammi Therapeutics is developing targeted immunotherapies designed to focus immune activation at the tumor site, minimizing systemic side effects. Their approach utilizes two platform technologies: Masked ImmunoCytokines (MICs) and Nammisomes. MICs consist of a tumor antigen-targeting antibody fused to a masked cytokine, activated selectively within the tumor microenvironment. Nammisomes are lipid-based nanoparticles that encapsulate prodrugs of immune modulators, delivering them directly to the tumor. These platforms aim to modulate multiple immune functions in different cell types while maintaining the immune agents in an inactive state in circulation until they reach the tumor.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking more effective and less toxic immunotherapeutic options for cancer treatment.
Features
- Masked ImmunoCytokines (MICs): Antibody-cytokine fusion proteins with protease-cleavable masks for tumor-specific activation.
- Nammisomes: Solid lipid nanoparticles for targeted delivery of immune-modulating prodrugs.
- QXL138AM: An anti-CD138 targeting antibody fused to IFNa2 cytokine with a masking peptide.
- SLNP-IC1: A solid lipid nanoparticle incorporating a Doxorubicin prodrug (IC1).
- NTI-121: A solid lipid nanoparticle incorporating a Doxorubicin prodrug (IC1) and a Toll Receptor 7 agonist prodrug (TR12).
- Designed to modulate multiple immune functions in different cell types.
- Incorporates mechanisms of maintaining the immune agents in an inactive state in circulation, while allowing them to be activated at the tumor site.
- Provides a mechanism for selectively targeting the therapeutic to the tumor environment.